David J Maron

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4726077/david-j-maron-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73 papers	7,091 citations	24 h-index	84 g-index
91 ext. papers	9,505 ext. citations	11.3 avg, IF	5.25 L-index

#	Paper	IF	Citations
73	Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statement.. *American Journal of Preventive Cardiology*, **2022**, 9, 100318	1.9	4
72	Predictors of outcome in the ISCHEMIA-CKD trial: Anatomy versus ischemia. *American Heart Journal* , **2022**, 243, 187-200	4.9	0
71	Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial.. *Journal of the American College of Cardiology*, **2022**, 79, 651-661	15.1	1
70	Comprehensive Quality of Life Outcomes with Invasive versus Conservative Management of Chronic Coronary Disease in ISCHEMIA.. *Circulation*, **2022**,	16.7	2
69	Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial.. *Circulation: Cardiovascular Interventions*, **2022**, CIRCINTERVENTIONS121010925	6	1
68	Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop. *JACC: Cardiovascular Imaging*, **2021**, 14, 1454-1465	8.4	8
67	Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. *Circulation*, **2021**, 143, 790-804	16.7	21
66	Response by Bangalore et al to Letter Regarding Article, "Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials". *Circulation*, **2021**, 143, e809-e810	16.7	
65	Response by Lopes et al to Letter Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial". *Circulation*, **2021**, 143, e961-e962	16.7	
64	Automated coronary calcium scoring using deep learning with multicenter external validation. *Npj Digital Medicine*, **2021**, 4, 88	15.7	11
63	Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial. *Journal of the American College of Cardiology*, **2021**, 78, 348-361	15.1	10
62	CT Angiography Followed by Invasive Angiography in Patients With Moderate or Severe Ischemia-Insights From the ISCHEMIA Trial. *JACC: Cardiovascular Imaging*, **2021**, 14, 1384-1393	8.4	11
61	Digital Health Interventions for Cardiac Rehabilitation: Systematic Literature Review. *Journal of Medical Internet Research*, **2021**, 23, e18773	7.6	13
60	Response by Chaitman et al to Letter Regarding Article, "Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons". *Circulation*, **2021**, 144, e14-e15	16.7	1
59	Disparity in the Setting of Incident Heart Failure Diagnosis. *Circulation: Heart Failure*, **2021**, 14, e008538	7.6	2
58	Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study. *Circulation*, **2021**, 144, 1008-1023	16.7	14
57	Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. *Circulation*, **2021**, 144, 1024-1038	16.7	15

56	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. *Circulation*, **2021**, 144, 1380-1395	16.7	5
55	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. *JAMA Cardiology*, **2021**, 6, 1023-1031	16.2	1
54	Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. *European Heart Journal*, **2021**,	9.5	4
53	Risk Prediction Tool for Assessing the Probability of Death or Myocardial Infarction in Patients With Stable Coronary Artery Disease. *American Journal of Cardiology*, **2020**, 130, 1-6	3	1
52	The Project Baseline Health Study: a step towards a broader mission to map human health. *Npj Digital Medicine*, **2020**, 3, 84	15.7	10
51	Initial Invasive or Conservative Strategy for Stable Coronary Disease. *New England Journal of Medicine*, **2020**, 382, 1395-1407	59.2	642
50	Management of Coronary Disease in Patients with Advanced Kidney Disease. *New England Journal of Medicine*, **2020**, 382, 1608-1618	59.2	159
49	Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. *New England Journal of Medicine*, **2020**, 382, 1408-1419	59.2	138
48	Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. *New England Journal of Medicine*, **2020**, 382, 1619-1628	59.2	32
47	Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia: Secondary Analysis of the ISCHEMIA Randomized Clinical Trial. *JAMA Cardiology*, **2020**, 5, 773-786	16.2	44
46	Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials. *Circulation*, **2020**, 142, 841-857	16.7	54
45	Cardiorespiratory Fitness, Body Mass Index, and Markers of Insulin Resistance in Apparently Healthy Women and Men. *American Journal of Medicine*, **2020**, 133, 825-830.e2	2.4	6
44	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial. *Circulation*, **2020**, 142, 1725-1735	16.7	27
43	The Comparative Effect of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on 10-Year and Lifetime Atherosclerotic Cardiovascular Disease Risk. *Obesity Surgery*, **2019**, 29, 3111-3117	3.7	8
42	Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. *Journal of the American College of Cardiology*, **2019**, 73, 2049-2058	15.1	12
41	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. *JAMA Cardiology*, **2019**, 4, 273-286	16.2	65
40	Coronary artery calcium testing: A call for universal coverage. *Preventive Medicine Reports*, **2019**, 15, 100879	2.6	7
39	Studies Evaluating Statin Adherence and Outcome Should Adjust for Smoking Persistence and Antiplatelet Treatment Discontinuation-Reply. *JAMA Cardiology*, **2019**, 4, 832-833	16.2	

38	Controversies in Diagnostic Imaging of Patients With Suspected Stable and Acute Chest Pain Syndromes. *JACC: Cardiovascular Imaging*, **2019**, 12, 1254-1278	8.4	3
37	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. *Journal of the American College of Cardiology*, **2019**, 74, 1926-1942	15.1	19
36	Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease. *Circulation: Cardiovascular Quality and Outcomes*, **2019**, 12, e005079	5.8	11
35	Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. *JAMA Cardiology*, **2019**, 4, 206-213	16.2	108
34	Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial. *Circulation: Cardiovascular Quality and Outcomes*, **2019**, 12, e006002	5.8	14
33	Association of Educational Attainment and Cardiovascular Risk in Hispanic Individuals: Findings From the Cooper Center Longitudinal Study. *JAMA Cardiology*, **2019**, 4, 43-50	16.2	4
32	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. *American Heart Journal*, **2018**, 201, 124-135	4.9	132
31	Dietary Patterns and Long-Term Survival: A Retrospective Study of Healthy Primary Care Patients. *American Journal of Medicine*, **2018**, 131, 48-55	2.4	17
30	ISCHEMIA: Establishing the Primary End Point. *Circulation: Cardiovascular Quality and Outcomes*, **2018**, 11, e004791	5.8	4
29	The Reply. *American Journal of Medicine*, **2018**, 131, e211	2.4	
28	Cost-effectiveness of on-pump and off-pump coronary artery bypass grafting for patients with coronary artery disease: Results from the MASS III trial. *International Journal of Cardiology*, **2018**, 273, 63-68	3.2	1
27	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. *American Heart Journal*, **2018**, 205, 42-52	4.9	27
26	Frequency of Statin Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dl from the Veterans Affairs Health System. *American Journal of Cardiology*, **2018**, 122, 756-761	3	17
25	Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. *Journal of the American College of Cardiology*, **2018**, 72, 2297-2305	15.1	24
24	Planning and Conducting the ISCHEMIA Trial. *Circulation*, **2018**, 138, 1384-1386	16.7	11
23	Intensity of Statin Treatment and Mortality-Reply. *JAMA Cardiology*, **2017**, 2, 928-929	16.2	2
22	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. *American Heart Journal*, **2017**, 190, 135-139	4.9	21
21	Relationship between simple markers of insulin resistance and coronary artery calcification. *Journal of Clinical Lipidology*, **2017**, 11, 1007-1012	4.9	7

20	Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. *JAMA Cardiology*, **2017**, 2, 47-54	16.2	92
19	Risk Estimates for Atherosclerotic Cardiovascular Disease in Adults With Congenital Heart Disease. *American Journal of Cardiology*, **2017**, 119, 112-118	3	37
18	Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial. *American Heart Journal*, **2016**, 173, 108-17	4.9	17
17	Conservative versus invasive stable ischemic heart disease management strategies: what do we plan to learn from the ISCHEMIA trial?. *Future Cardiology*, **2016**, 12, 35-44	1.3	4
16	Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. *Journal of the American College of Cardiology*, **2016**, 67, 81-99	15.1	70
15	Treatment of Patients With Stable Ischemic Heart Disease--Reply. *JAMA - Journal of the American Medical Association*, **2016**, 315, 1905-6	27.4	
14	Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines. *American Heart Journal*, **2016**, 182, 97-102	4.9	34
13	Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial). *American Journal of Cardiology*, **2015**, 116, 167-73	3	14
12	Identification of Emergency Department Patients With Acute Heart Failure at Low Risk for 30-Day Adverse Events: The STRATIFY Decision Tool. *JACC: Heart Failure*, **2015**, 3, 737-47	7.9	52
11	Effect of baseline exercise capacity on outcomes in patients with stable coronary heart disease (a post hoc analysis of the clinical outcomes utilizing revascularization and aggressive drug evaluation trial). *American Journal of Cardiology*, **2015**, 116, 1509-15	3	2
10	Evidence-Based Management of Stable Ischemic Heart Disease: Challenges and Confusion. *JAMA - Journal of the American Medical Association*, **2015**, 314, 1917-8	27.4	10
9	Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. *International Journal of Clinical Rheumatology*, **2015**, 10, 365-381	1.5	14
8	Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia. *JACC: Cardiovascular Interventions*, **2014**, 7, 195-201	5	125
7	Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. *JACC: Cardiovascular Imaging*, **2014**, 7, 593-604	8.4	127
6	Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. *American Heart Journal*, **2012**, 164, 243-50	4.9	131
5	Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. *Circulation*, **2008**, 117, 1283-91	16.7	1183
4	Health-risk appraisal with or without disease management for worksite cardiovascular risk reduction. *Journal of Cardiovascular Nursing*, **2008**, 23, 513-8	2.1	14
3	Optimal medical therapy with or without PCI for stable coronary disease. *New England Journal of Medicine*, **2007**, 356, 1503-16	59.2	3073

2	Flavonoids for reduction of atherosclerotic risk. *Current Atherosclerosis Reports*, **2004**, 6, 73-8	6	85
1	Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. *Archives of Internal Medicine*, **2003**, 163, 1448-53		161